Hanan Hussein AlkharboushKing Khalid Hospital-Najran, Saudi Arabia
Title: The cost-effectiveness of using epoetin-beta versus darbepoetin-alfa for the treatment of anemia among chronic hemodialysis patients
The principal objective of this study was to compare the cost-effectiveness of the use of short-acting erythropoietin with the long-acting one to maintain serum hemoglobin (Hb) concentration within the range of 10.5-12 g/dL. It was a retrospective cohort study involving patients diagnosed with stage 5 CKD. We compared the cost-effectiveness of long-acting erythropoietin with the short-acting. The decision analysis model and Markov model were established to simulate a cohort of 55-year-old patients to estimate the incremental cost and quality-adjusted life-year (QALY) for chronic hemodialysis patients (CHP) treated with either darbepoetin-alfa or epoetin-beta for at least nine months. The incremental cost per QALY was the main outcome marker for using both medications. Serum HB levels were monitored on a monthly basis and costs were calculated. We observed a significant difference between the percentage of patients successfully treated with epoetin-beta and those managed with darbepoetin-alfa (80.4% vs. 63.92%, p=0.01) with considerably less cardiovascular side effects. The average annual cost per patient was estimated at $919.47 and $12,319.41 for epoetin-beta and darbepoetin-alfa respectively. Also, the average effectiveness was 0.58 for darbepoetin-alfa vs. 0.61 for epoetin-beta. The average cost-effectiveness ratio was $980.25 and $15,023.66 with an incremental cost difference of -$966 in favor of epoetin-beta compared to darbepoetin-alfa.
Hanan Hussein Clinical Pharmacy Resident at KKH-Najran, Graduated 2020 as a PharmD from collage of Pharmacy-Tabuk University. Currently Participating as a part of multiple studies in the field of Renal Replacement Therapy and Transplantation.